Delayed nausea and vomiting from carboplatin doublet chemotherapy

Figures & data

Table 1. Demographics of patients enrolled on study.

Variable	Total (%) N = 105
Age (median)	64.8 years
Gender
Male	62 (59%)
Female	43 (41%)
Race
White	83 (79%)
Black or African-American	19 (18%)
Native American or Alaskan Nation	2 (2%)
Asian	1 (1%)
Tumor type
Non-small cell lung	83 (79.0%)
Esophageal	7 (6.7%)
Small cell lung	7 (6.7%)
Mesothelioma	5 (4.8%)
Transitional cell	1 (1.0%)
Stage
I	2 (2.3%)
II	3 (3.4%)
III	19 (21.6%)
IV	64 (72.7%)
Smoking status
Current	32 (33.0%)
Former	59 (60.8%)
Never	6 (6.2%)

Table 2. Incidence of acute and delayed nausea and vomiting in patients following Cycle 1 of carboplatin containing chemotherapy according to gender.

Type of emesis	Time points	Overall (%)	Male (%)	Female (%)
Acute	24 hours	10 (10%)	7 (11.9%)	3 (7.3%)
Delayed	48 hours	14 (14.1%)	10 (16.9%)	4 (10%)
	72 hours	22 (22.4%)	14 (24.1%)	8 (20%)
	96 hours	23 (23.5%)	16 (27.1%)	7 (17.9%)

Table 3. Incidence of acute and delayed nausea and vomiting in patients following Cycle 3 of carboplatin containing chemotherapy according to gender.

Type of emesis	Time points	Overall (%)	Male (%)	Female (%)
Acute	24 hours	2 (4.1%)	1 (3.6%)	1 (4.8%)
Delayed	48 hours	6 (12.8%)	4 (14.3%)	2 (10.5%)
	72 hours	7 (14.6%)	4 (14.3%)	3 (15%)
	96 hours	8 (16%)	5 (17.2%)	3 (14.3%)

Table 4. Risk factors for delayed nausea and vomiting following Cycle 1 of carboplatin containing chemotherapy based on univariate analysis.

			Incidence
Covariate	Statistics	Level	No emesis	Moderate-severe emesis	Parametric p-value*
Gender	N (%)	Male	39 (56.52)	20 (66.67)	0.344
	N (%)	Female	30 (43.48)	10 (33.33)
Smoking status	N (%)	Never/Former	38 (61.29)	24 (82.76)	0.041
	N (%)	Current	24 (38.71)	5 (17.24)
Age	N		69	30	0.704
	Mean		64.85	64
	Std dev		10.38	9.88

*The parametric p-value is calculated by ANOVA for numerical covariates and χ²-test for categorical covariates.

Table 5. Breakthrough anti-emetic use among patients following Cycle 1 of carboplatin containing chemotherapy.

Breakthrough anti-emetic	Frequency	Cumulative frequency
Lorazepam	2	2
Lorazepam and prochlorperazine	1	3
Prochlorperazine	13	16
Prochlorperazine and metoclopramide	1	17
Metoclopramide	2	19
Dexamethasone	1	20